Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Journey Medical Corporation (DERM)
USD7.28
+0.16 (+2.30%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
9237 East Via de Ventura Boulevard 85258
Scottsdale, AZ, US
Scottsdale, AZ, US
CEO
Claude Maraoui
Website
journeymedicalcorp.com
IPO
2021-11-12
CIK 1867066 ISIN US48115J1097
Description
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.28
+0.16 (+2.30%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
273.0K
Beta
1.07
Float Shares
14.62M
Free Float %
53.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.59% | +4.22% | -0.19% | -32.86% | -32.51% | -32.68% | -17.88% | +257.93% | -45.37% | -45.37% | -45.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
7.28
Low
10.50
+44.2%
Consensus
11.75
+61.3%
Median
11.75
+61.3%
High
13.00
+78.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
13.00
+78.5%
|
| All Time | 2 |
11.75
+61.3%
|
Quality scores
Altman Z-Score
0.70
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.2% ★ Q1'26: +21.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+34.7% ★ Q1'26: +55.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-31.5% Q1'26: +18.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-13.2% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-103.7% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+19.9% Q1'26: +20.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.03× Q1'26: -4.27× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
63.13M
est: 66.01M (-4.4%)
|
73.67M
est: 74.27M (-0.8%)
|
79.18M
est: 80.00M (-1.0%)
|
56.13M
est: 56.52M (-0.7%)
|
61.86M
est: 64.65M (-4.3%)
|
84.75M
79.57M – 89.92M
+31.1% YoY
|
138.32M
131.69M – 144.95M
+63.2% YoY
|
199.62M
198.76M – 200.49M
+44.3% YoY
|
225.68M
209.60M – 245.69M
+13.1% YoY
|
241.33M
224.13M – 262.73M
+6.9% YoY
|
| EBITDA |
-32.77M
est: -9.91M (-230.6%)
|
-23.18M
est: -11.15M (-107.9%)
|
1.92M
est: -16.33M (+111.8%)
|
-8.40M
est: -11.54M (+27.2%)
|
-3.83M
est: -13.20M (+71.0%)
|
-17.30M
-18.36M – -16.24M
-31.1% YoY
|
-28.24M
-29.59M – -26.89M
-63.2% YoY
|
-40.76M
-40.93M – -40.58M
-44.3% YoY
|
-46.08M
-50.16M – -42.79M
-13.1% YoY
|
-49.27M
-53.64M – -45.76M
-6.9% YoY
|
| EBIT |
-35.33M
est: -13.12M (-169.3%)
|
-27.55M
est: -14.76M (-86.6%)
|
-1.93M
est: -20.83M (+90.7%)
|
-11.91M
est: -14.72M (+19.1%)
|
-8.17M
est: -16.84M (+51.5%)
|
-22.07M
-23.42M – -20.72M
-31.1% YoY
|
-36.02M
-37.75M – -34.30M
-63.2% YoY
|
-51.99M
-52.21M – -51.76M
-44.3% YoY
|
-58.77M
-63.99M – -54.59M
-13.1% YoY
|
-62.85M
-68.42M – -58.37M
-6.9% YoY
|
| Net Income |
-43.99M
est: -53.53M (+17.8%)
|
-29.63M
est: -31.80M (+6.8%)
|
-3.85M
est: -5.49M (+29.9%)
|
-14.67M
est: -24.50M (+40.1%)
|
-11.43M
est: -11.43M (+0.0%)
|
1.78M
1.50M – 2.06M
+115.5% YoY
|
24.13M
20.80M – 28.87M
+1,258.5% YoY
|
49.80M
43.12M – 66.63M
+106.4% YoY
|
34.30M
31.12M – 38.25M
-31.1% YoY
|
41.52M
37.68M – 46.31M
+21.1% YoY
|
| SGA |
39.83M
est: 35.76M (+11.4%)
|
59.47M
est: 40.24M (+47.8%)
|
43.91M
est: 54.82M (-19.9%)
|
40.20M
est: 38.73M (+3.8%)
|
44.37M
est: 44.30M (+0.2%)
|
58.07M
54.52M – 61.62M
+31.1% YoY
|
94.78M
90.24M – 99.32M
+63.2% YoY
|
136.79M
136.20M – 137.38M
+44.3% YoY
|
154.64M
143.63M – 168.36M
+13.1% YoY
|
165.37M
153.58M – 180.03M
+6.9% YoY
|
| EPS |
-2.54
est: -2.62 (+3.1%)
|
-1.69
est: -1.56 (-8.6%)
|
-0.21
est: -0.22 (+5.5%)
|
-0.72
est: -1.00 (+28.0%)
|
-0.47
est: -0.48 (+2.1%)
|
0.07
0.06 – 0.08
+115.1% YoY
|
1.02
0.85 – 1.18
+1,303.4% YoY
|
2.24
1.76 – 2.72
+120.1% YoY
|
1.40
1.27 – 1.56
-37.5% YoY
|
1.70
1.54 – 1.89
+21.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.76M
OE per share TTM
-0.29
Owner's Yield
-4.77%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
19.02M
Insider transactions (90d)
3
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fortress Biotech, Inc. | 10.01M | 56.90% | 10.01M | — | 10.01M | — | HC | — | 2022-08-17 | ↗ |
| 2 | Bryant R. Riley | 939.7K | 5.60% | 75.0K | 864.7K | 75.0K | 864.7K | IN | Citizenship or Place of Organization | 2022-02-11 | ↗ |
| 3 | B. Riley Financial, Inc. | 864.7K | 5.20% | — | 864.7K | — | 864.7K | CO | Citizenship or Place of Organization | 2022-02-11 | ↗ |
| 4 | B. Riley Securities, Inc. | 864.7K | 5.20% | — | 864.7K | — | 864.7K | BD | Citizenship or Place of Organization | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-56 vs prev Q
New positions
5
Closed positions
61
Increased
14
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 1.85M +— (+0.0%) | 14.30M +1.1M (+8.3%) | 7.43% -0.532 pp | 0.71% +0.198 pp | USD4.05 +90.4% | 10 qtrs — |
| 2 | WASATCH ADVISORS LP | 1.32M +10.0K (+0.8%) | 10.15M +847.8K (+9.1%) | 5.27% -0.335 pp | 0.06% +0.010 pp | USD6.27 +23.0% | 4 qtrs — |
| 3 | OPALEYE MANAGEMENT INC. | 975.0K +3.9K (+0.4%) | 7.52M +603.3K (+8.7%) | 3.91% -0.263 pp | 0.99% +0.014 pp | USD7.04 +9.5% | 4 qtrs — |
| 4 | J. GOLDMAN & CO LP | 798.4K +798.4K (+100.0%) | 6.16M +6.2M (+100.0%) | 3.20% +3.199 pp | 0.16% +0.162 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 5 | VANGUARD GROUP INC | 764.1K +148.9K (+24.2%) | 5.89M +1.5M (+34.5%) | 3.06% +0.420 pp | 0.00% +0.000 pp | USD5.73 +34.6% | 15 qtrs — |
| 6 | BLACKROCK, INC. | 719.8K +86.7K (+13.7%) | 5.55M +1.0M (+23.1%) | 2.88% +0.166 pp | 0.00% +0.000 pp | USD7.12 +8.3% | 6 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 457.8K +457.8K (+100.0%) | 3.53M +3.5M (+100.0%) | 1.83% +1.834 pp | 0.00% +0.002 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 8 | PALE FIRE CAPITAL SE | 444.6K +216.1K (+94.5%) | 3.43M +1.8M (+110.7%) | 1.78% +0.800 pp | 0.23% +0.052 pp | USD7.33 +5.2% | 4 qtrs — |
| 9 | SUMMIT FINANCIAL, LLC | 390.4K +10.6K (+2.8%) | 3.01M +305.7K (+11.3%) | 1.56% -0.067 pp | 0.04% +0.003 pp | USD7.14 +8.0% | 2 qtrs — |
| 10 | ESSEX INVESTMENT MANAGEMENT CO LLC | 346.0K -8.0K (-2.3%) | 2.67M +146.9K (+5.8%) | 1.39% -0.134 pp | 0.41% +0.021 pp | USD7.16 +7.7% | 3 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 314.0K +36.1K (+13.0%) | 2.42M +442.5K (+22.4%) | 1.26% +0.065 pp | 0.00% +0.000 pp | USD5.98 +28.9% | 14 qtrs — |
| 12 | UBS GROUP AG | 290.2K +145.0K (+99.9%) | 2.24M +1.2M (+116.4%) | 1.16% +0.539 pp | 0.00% +0.000 pp | USD7.27 +6.1% | 5 qtrs — |
| 13 | IKARIAN CAPITAL, LLC | 251.4K +251.4K (+100.0%) | 1.94M +1.9M (+100.0%) | 1.01% +1.007 pp | 0.15% +0.151 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 244.0K -3.9K (-1.6%) | 1.88M +116.2K (+6.6%) | 0.98% -0.087 pp | 0.00% +0.001 pp | USD5.47 +41.0% | 11 qtrs — |
| 15 | AMERICAN FINANCIAL GROUP INC | 180.0K +— (+0.0%) | 1.39M +106.2K (+8.3%) | 0.72% -0.052 pp | 0.50% +0.009 pp | USD5.38 +43.3% | 17 qtrs — |
| 16 | STATE STREET CORP | 173.3K +27.3K (+18.7%) | 1.34M +296.6K (+28.5%) | 0.69% +0.068 pp | 0.00% +0.000 pp | USD6.77 +13.9% | 10 qtrs — |
| 17 | LEGATO CAPITAL MANAGEMENT LLC | 111.7K +9.8K (+9.6%) | 861.2K +135.7K (+18.7%) | 0.45% +0.010 pp | 0.07% -0.005 pp | USD7.21 +6.9% | 3 qtrs — |
| 18 | SEI INVESTMENTS CO | 109.4K +109.4K (+100.0%) | 843.1K +843.1K (+100.0%) | 0.44% +0.438 pp | 0.00% +0.001 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 19 | NORTHERN TRUST CORP | 93.7K +927.0 (+1.0%) | 722.2K +61.9K (+9.4%) | 0.38% -0.023 pp | 0.00% +0.000 pp | USD6.89 +11.9% | 9 qtrs — |
| 20 | EAM INVESTORS, LLC | 89.4K +— (+0.0%) | 689.2K +52.7K (+8.3%) | 0.36% -0.026 pp | 0.08% +0.004 pp | USD7.18 +7.4% | 3 qtrs — |
| 21 | CITADEL ADVISORS LLC | 69.4K +55.0K (+382.4%) | 535.2K +432.7K (+422.4%) | 0.28% +0.216 pp | 0.00% +0.000 pp | USD7.59 +1.6% | 5 qtrs — |
| 22 | BOOTHBAY FUND MANAGEMENT, LLC | 67.4K +67.4K (+100.0%) | 520.0K +520.0K (+100.0%) | 0.27% +0.270 pp | 0.01% +0.008 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 23 | GENEOS WEALTH MANAGEMENT INC. | 63.3K +— (+0.0%) | 487.9K +37.3K (+8.3%) | 0.25% -0.018 pp | 0.01% +0.001 pp | USD5.37 +43.6% | 7 qtrs — |
| 24 | LAZARD ASSET MANAGEMENT LLC | 62.5K +62.5K (+100.0%) | 482.1K +482.1K (+100.0%) | 0.25% +0.251 pp | 0.00% +0.001 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 25 | DIAMETRIC CAPITAL, LP | 51.7K +51.7K (+100.0%) | 398.5K +398.5K (+100.0%) | 0.21% +0.207 pp | 0.11% +0.107 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 26 | PVG ASSET MANAGEMENT CORP | 51.6K -81.3K (-61.2%) | 398.1K -548.2K (-57.9%) | 0.21% -0.364 pp | 0.85% -2.637 pp | USD5.40 +42.8% | 7 qtrs — |
| 27 | AQR CAPITAL MANAGEMENT LLC | 51.3K +436.0 (+0.9%) | 395.3K +33.4K (+9.2%) | 0.21% -0.013 pp | 0.00% +0.000 pp | USD7.13 +8.1% | 2 qtrs — |
| 28 | CREATIVE PLANNING | 50.5K +10.0 (+0.0%) | 389.4K +29.9K (+8.3%) | 0.20% -0.015 pp | 0.00% +0.000 pp | USD6.32 +22.0% | 15 qtrs — |
| 29 | STATE OF WISCONSIN INVESTMENT BOARD | 45.8K +10.0K (+27.8%) | 353.1K +97.9K (+38.4%) | 0.18% +0.030 pp | 0.00% +0.000 pp | USD7.25 +6.3% | 2 qtrs — |
| 30 | INTEGRATED WEALTH CONCEPTS LLC | 44.0K -330.0 (-0.7%) | 339.4K +23.6K (+7.5%) | 0.18% -0.014 pp | 0.00% +0.001 pp | USD5.37 +43.6% | 7 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 35.5K +5.1K (+16.6%) | 273.8K +56.9K (+26.3%) | 0.14% +0.012 pp | 0.00% +0.000 pp | USD7.26 +6.2% | 3 qtrs — |
| 32 | ENVESTNET ASSET MANAGEMENT INC | 33.6K -27.4K (-44.9%) | 259.0K -175.0K (-40.3%) | 0.13% -0.127 pp | 0.00% +0.000 pp | USD4.92 +56.7% | 8 qtrs — |
| 33 | GLADSTONE INSTITUTIONAL ADVISORY LLC | 29.1K +500.0 (+1.8%) | 224.1K +20.7K (+10.2%) | 0.12% -0.006 pp | 0.01% +0.001 pp | USD5.51 +39.9% | 7 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 28.7K +4.2K (+17.3%) | 221.6K +47.2K (+27.1%) | 0.12% +0.010 pp | 0.00% +0.000 pp | USD7.26 +6.2% | 3 qtrs — |
| 35 | BNP PARIBAS ARBITRAGE, SNC | 27.8K +25.1K (+934.9%) | 214.5K +195.3K (+1,020.7%) | 0.11% +0.100 pp | 0.00% +0.000 pp | USD7.66 +0.7% | 3 qtrs — |
| 36 | MORGAN STANLEY | 26.5K +5.8K (+27.8%) | 204.3K +56.7K (+38.4%) | 0.11% +0.017 pp | 0.00% +0.000 pp | USD6.73 +14.6% | 5 qtrs — |
| 37 | BARCLAYS PLC | 22.5K +5.0K (+28.2%) | 173.6K +48.6K (+38.8%) | 0.09% +0.015 pp | 0.00% +0.000 pp | USD7.30 +5.6% | 3 qtrs — |
| 38 | JUMP FINANCIAL, LLC | 20.2K +6.4K (+46.1%) | 155.6K +57.3K (+58.3%) | 0.08% +0.022 pp | 0.00% +0.001 pp | USD7.31 +5.5% | 2 qtrs — |
| 39 | COLONY GROUP, LLC | 19.7K +19.7K (+100.0%) | 152.0K +152.0K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 40 | MARSHALL WACE, LLP | 19.4K +19.4K (+100.0%) | 149.6K +149.6K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 41 | GOLDMAN SACHS GROUP INC | 19.2K -14.9K (-43.6%) | 148.1K -94.4K (-38.9%) | 0.08% -0.069 pp | 0.00% +0.000 pp | USD7.12 +8.3% | 2 qtrs — |
| 42 | OCCUDO QUANTITATIVE STRATEGIES LP | 18.9K +3.4K (+22.3%) | 145.8K +35.7K (+32.4%) | 0.08% +0.009 pp | 0.01% -0.004 pp | USD7.23 +6.6% | 2 qtrs — |
| 43 | INVESCO LTD. | 16.5K +16.5K (+100.0%) | 127.4K +127.4K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 44 | XTX TOPCO LTD | 16.4K +16.4K (+100.0%) | 126.4K +126.4K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.003 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 45 | NEUBERGER BERMAN GROUP LLC | 16.0K -3.8K (-19.2%) | 123.0K -17.5K (-12.5%) | 0.06% -0.021 pp | 0.00% +0.000 pp | USD5.38 +43.3% | 17 qtrs — |
| 46 | WELLS FARGO & COMPANY/MN | 15.7K +8.2K (+109.1%) | 121.4K +67.8K (+126.4%) | 0.06% +0.031 pp | 0.00% +0.000 pp | USD7.45 +3.5% | 3 qtrs — |
| 47 | NUVEEN, LLC | 15.7K +— (+0.0%) | 121.1K +9.3K (+8.3%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 48 | SJS INVESTMENT CONSULTING INC. | 15.0K +— (+0.0%) | 115.7K +8.9K (+8.3%) | 0.06% -0.004 pp | 0.01% +0.000 pp | USD7.12 +8.3% | 2 qtrs — |
| 49 | SALEM INVESTMENT COUNSELORS INC | 14.3K +2.2K (+18.2%) | 110.3K +24.1K (+28.0%) | 0.06% +0.005 pp | 0.00% +0.001 pp | USD7.21 +6.9% | 2 qtrs — |
| 50 | JANE STREET GROUP, LLC | 14.0K +14.0K (+100.0%) | 107.6K +107.6K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 51 | ATRIA INVESTMENTS, INC | 13.1K -12.6K (-49.0%) | 100.8K -81.7K (-44.7%) | 0.05% -0.058 pp | 0.00% -0.001 pp | USD5.38 +43.3% | 7 qtrs — |
| 52 | TITLEIST ASSET MANAGEMENT, LLC | 12.9K +— (+0.0%) | 99.5K +7.6K (+8.3%) | 0.05% -0.004 pp | 0.01% +0.000 pp | USD5.69 +35.5% | 6 qtrs — |
| 53 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.2K +12.2K (+100.0%) | 94.4K +94.4K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 5 qtrs — |
| 54 | DEUTSCHE BANK AG\ | 11.6K +11.6K (+100.0%) | 89.1K +89.1K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 3 qtrs — |
| 55 | BANK OF AMERICA CORP /DE/ | 10.8K -10.7K (-49.8%) | 83.3K -70.0K (-45.7%) | 0.04% -0.049 pp | 0.00% +0.000 pp | USD7.12 +8.3% | 9 qtrs — |
| 56 | RHUMBLINE ADVISERS | 9.8K -1.3K (-12.1%) | 75.3K -3.8K (-4.8%) | 0.04% -0.009 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 57 | ADVISOR GROUP HOLDINGS, INC. | 9.0K -3.1K (-25.7%) | 69.7K -18.0K (-20.5%) | 0.04% -0.016 pp | 0.00% +0.000 pp | USD4.61 +67.2% | 9 qtrs — |
| 58 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 6.7K +1.1K (+18.9%) | 51.4K +11.5K (+28.8%) | 0.03% +0.003 pp | 0.00% +0.000 pp | USD7.26 +6.2% | 3 qtrs — |
| 59 | JPMORGAN CHASE & CO | 5.8K +900.0 (+18.2%) | 45.0K +9.9K (+28.0%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD7.26 +6.2% | 3 qtrs — |
| 60 | ROYAL BANK OF CANADA | 5.7K +328.0 (+6.1%) | 44.0K +6.0K (+15.8%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD7.09 +8.7% | 7 qtrs — |
| 61 | NEW YORK STATE COMMON RETIREMENT FUND | 5.5K +— (+0.0%) | 42.4K +3.2K (+8.3%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 62 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 4.0K +— (+0.0%) | 30.9K +2.4K (+8.3%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 63 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.5K +743.0 (+43.0%) | 19.0K +6.7K (+54.9%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD7.30 +5.6% | 17 qtrs — |
| 64 | LEGAL & GENERAL GROUP PLC | 1.3K +— (+0.0%) | 10.4K +794.0 (+8.3%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 65 | AMERITAS INVESTMENT PARTNERS, INC. | 1.2K +— (+0.0%) | 9.6K +731.0 (+8.3%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 66 | RUSSELL INVESTMENTS GROUP, LTD. | 1.1K -7.5K (-87.0%) | 8.6K -52.4K (-85.9%) | 0.00% -0.032 pp | 0.00% 0.000 pp | USD7.12 +8.3% | 2 qtrs — |
| 67 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 886.00 +128.0 (+16.9%) | 6.8K +1.4K (+26.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.26 +6.2% | 3 qtrs — |
| 68 | SIMPLEX TRADING, LLC | 434.00 +434.0 (+100.0%) | 3.3K +3.3K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 69 | AMALGAMATED BANK | 452.00 +37.0 (+8.9%) | 3.0K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.22 +6.8% | 3 qtrs — |
| 70 | CITIGROUP INC | 326.00 -193.0 (-37.2%) | 2.5K -1.2K (-32.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD7.18 +7.4% | 3 qtrs — |
| 71 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 300.00 +— (+0.0%) | 2.3K +177.0 (+8.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD5.37 +43.6% | 7 qtrs — |
| 72 | FMR LLC | 196.00 +177.0 (+931.6%) | 1.5K +1.4K (+1,017.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD7.65 +0.8% | 4 qtrs — |
| 73 | GAMMA INVESTING LLC | 182.00 +18.0 (+11.0%) | 1.4K +235.0 (+20.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.17 +7.5% | 2 qtrs — |
| 74 | FEDERATED HERMES, INC. | 144.00 +144.0 (+100.0%) | 1.1K +1.1K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD7.71 +0.0% | 1 qtrs NEW |
| 75 | STERLING CAPITAL MANAGEMENT LLC | 80.00 +50.0 (+166.7%) | 617.00 +403.0 (+188.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.50 +2.8% | 3 qtrs — |
| 76 | PNC FINANCIAL SERVICES GROUP, INC. | 74.00 +74.0 (+100.0%) | 571.00 +571.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.70 +0.1% | 1 qtrs NEW |
| 77 | BUCKINGHAM STRATEGIC PARTNERS | — -20.0K (-100.0%) | — -179.1K (-100.0%) | 0.00% -0.086 pp | 0.00% -0.002 pp | USD— | 3 qtrs SOLD |
| 78 | SRS CAPITAL ADVISORS, INC. | — -46.0 (-100.0%) | — -327.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 79 | WALLEYE CAPITAL LLC | — -22.6K (-100.0%) | — -160.6K (-100.0%) | 0.00% -0.097 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 80 | ALLEGIANCE FINANCIAL GROUP ADVISORY SERVICES LLC | — -10.0K (-100.0%) | — -71.2K (-100.0%) | 0.00% -0.043 pp | 0.00% -0.016 pp | USD— | 13 qtrs SOLD |
| 81 | KESTRA ADVISORY SERVICES, LLC | — -10.2K (-100.0%) | — -72.7K (-100.0%) | 0.00% -0.044 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 82 | KOVITZ INVESTMENT GROUP PARTNERS, LLC | — -21.7K (-100.0%) | — -154.6K (-100.0%) | 0.00% -0.093 pp | 0.00% -0.001 pp | USD— | 6 qtrs SOLD |
| 83 | BRIGHTON JONES LLC | — -16.8K (-100.0%) | — -119.9K (-100.0%) | 0.00% -0.072 pp | 0.00% -0.003 pp | USD— | 11 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.55% | 120.1K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.02% | 351.9K | 0.60% |
| 3 | Vanguard Russell 2000 Growth ETF VTWG | 0.01% | 120.0K | 0.06% |
| 4 | Vanguard Russell 2000 ETF VTWO | 0.00% | 650.1K | 0.06% |
| 5 | Vanguard Extended Market ETF VXF | 0.00% | 1.41M | 0.05% |
| 6 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 22.3K | 0.43% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 28.6K | 0.17% |
| 8 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 2.1K | 0.17% |
| 9 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 10.4K | 0.03% |
| 10 | Vanguard Total Stock Market ETF VTI | 0.00% | 4.89M | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
312.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+312,617
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Maraoui Claude | Director / Officer | A-Award | A | Common Stock, $0.0001 par value | 49,277 | 0.00 | — | 2,435,990 | D | ↗ |
| 2026-04-22 | Benesch Joseph | Officer | A-Award | A | Common Stock, $0.0001 par value | 28,907 | 0.00 | — | 261,371 | D | ↗ |
| 2026-04-22 | Alloush Ramsey | Officer | A-Award | A | Common Stock, $0.0001 par value | 46,863 | 0.00 | — | 598,543 | D | ↗ |
| 2025-08-25 | Maraoui Claude | Director / Officer | M-Exempt | A | Common Stock, $0.0001 par value | 1,250,000 | 0.07 | 81.3K | 2,397,590 | D | ↗ |
| 2025-08-05 | Toledano Miranda Jayne | Director | A-Award | A | Common Stock, $0.0001 par value | 20,000 | 0.00 | — | 108,618 | D | ↗ |
| 2025-08-05 | Smith Justin Adam | Director | A-Award | A | Common Stock, $0.0001 par value | 20,000 | 0.00 | — | 171,618 | D | ↗ |
| 2025-08-05 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock, $0.0001 par value | 50,000 | 0.00 | — | 211,146 | D | ↗ |
| 2025-08-05 | Pearce Michael Cooper | Director | A-Award | A | Common Stock, $0.0001 par value | 20,000 | 0.00 | — | 57,173 | D | ↗ |
| 2025-08-05 | Herskowitz Neil | Director | A-Award | A | Common Stock, $0.0001 par value | 20,000 | 0.00 | — | 108,618 | D | ↗ |
| 2025-06-25 | Toledano Miranda Jayne | Director | A-Award | A | Common Stock, $0.0001 par value | 7,173 | 0.00 | — | 88,618 | D | ↗ |
| 2025-06-25 | Smith Justin Adam | Director | A-Award | A | Common Stock, $0.0001 par value | 7,173 | 0.00 | — | 151,618 | D | ↗ |
| 2025-06-25 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock, $0.0001 par value | 7,173 | 0.00 | — | 161,146 | D | ↗ |
| 2025-06-25 | Pearce Michael Cooper | Director | A-Award | A | Common Stock, $0.0001 par value | 7,173 | 0.00 | — | 37,173 | D | ↗ |
| 2025-06-25 | Herskowitz Neil | Director | A-Award | A | Common Stock, $0.0001 par value | 7,173 | 0.00 | — | 88,618 | D | ↗ |
| 2025-06-17 | Maraoui Claude | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 82,915 | 6.31 | 523.2K | 82,915 | D | ↗ |
| 2025-06-17 | Benesch Joseph | Officer | A-Award | A | Common Stock, $0.0001 par value | 28,907 | 0.00 | — | 232,464 | D | ↗ |
| 2025-06-17 | Alloush Ramsey | Officer | A-Award | A | Stock Option (Right to Buy) | 62,795 | 6.31 | 396.2K | 62,795 | D | ↗ |
| 2025-05-02 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 4,834 | 6.84 | 33.1K | 2,348,313 | D | ↗ |
| 2025-05-02 | Benesch Joseph | Officer | S-Sale | D | Common Stock, $0.0001 par value | 2,409 | 6.84 | 16.5K | 203,557 | D | ↗ |
| 2025-05-02 | Alloush Ramsey | Officer | S-Sale | D | Common Stock, $0.0001 par value | 2,857 | 6.84 | 19.5K | 504,817 | D | ↗ |
| 2025-04-01 | Alloush Ramsey | Officer | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 507,674 | D | ↗ |
| 2025-03-11 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 49,271 | 5.01 | 246.8K | 2,003,147 | D | ↗ |
| 2025-03-07 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 14,905 | 5.01 | 74.7K | 2,052,418 | D | ↗ |
| 2025-03-06 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 25,551 | 5.04 | 128.8K | 2,067,323 | D | ↗ |
| 2025-03-05 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 18,147 | 5.13 | 93.1K | 2,092,874 | D | ↗ |
| 2025-03-04 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 28,901 | 5.04 | 145.7K | 2,111,021 | D | ↗ |
| 2025-03-03 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 23,508 | 5.19 | 122.0K | 2,139,922 | D | ↗ |
| 2025-02-21 | Benesch Joseph | Officer | S-Sale | D | Common Stock, $0.0001 par value | 1,365 | 5.19 | 7.1K | 45,966 | D | ↗ |
| 2024-08-01 | Benesch Joseph | Officer | S-Sale | D | Common Stock, $0.0001 par value | 9,324 | 5.47 | 51.0K | 47,331 | — | ↗ |
| 2024-07-23 | Benesch Joseph | Officer | S-Sale | D | Common Stock, $0.0001 par value | 4,055 | 5.40 | 21.9K | 56,655 | — | ↗ |
| 2024-07-19 | Pearce Michael Cooper | Director | A-Award | A | Common Stock, $0.0001 par value | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2024-07-09 | Pearce Michael Cooper | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-08 | Toledano Miranda Jayne | Director | A-Award | A | Common Stock, $0.0001 par value | 9,728 | 0.00 | — | 81,445 | — | ↗ |
| 2024-07-08 | Smith Justin Adam | Director | A-Award | A | Common Stock, $0.0001 par value | 9,728 | 0.00 | — | 144,445 | — | ↗ |
| 2024-07-08 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock, $0.0001 par value | 9,728 | 0.00 | — | 153,973 | — | ↗ |
| 2024-07-08 | Herskowitz Neil | Director | A-Award | A | Common Stock, $0.0001 par value | 9,728 | 0.00 | — | 81,445 | — | ↗ |
| 2024-05-01 | Maraoui Claude | Director / Officer | A-Award | A | Common Stock, $0.0001 par value | 175,000 | 0.00 | — | 2,353,147 | D | ↗ |
| 2024-05-01 | Benesch Joseph | Officer | A-Award | A | Common Stock, $0.0001 par value | 80,000 | 0.00 | — | 205,966 | D | ↗ |
| 2024-03-25 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock, $0.0001 par value | 10,000 | 3.04 | 30.4K | 144,245 | — | ↗ |
| 2024-03-22 | Smith Justin Adam | Director | P-Purchase | A | Common Stock, $0.0001 par value | 30,000 | 3.47 | 104.1K | 134,717 | — | ↗ |
| 2024-03-22 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock, $0.0001 par value | 20,000 | 3.40 | 68.0K | 134,245 | — | ↗ |
| 2024-03-22 | Maraoui Claude | Director / Officer | P-Purchase | A | Common Stock, $0.0001 par value | 10,000 | 3.48 | 34.8K | 2,163,430 | — | ↗ |
| 2024-02-22 | Benesch Joseph | Officer | S-Sale | D | Common Stock, $0.0001 par value | 2,450 | 3.75 | 9.2K | 60,710 | — | ↗ |
| 2024-01-03 | Maraoui Claude | Director / Officer | A-Award | A | Common Stock, $0.0001 par value | 175,000 | 0.00 | — | 2,178,147 | D | ↗ |
| 2024-01-03 | Benesch Joseph | Officer | A-Award | A | Common Stock, $0.0001 par value | 80,000 | 0.00 | — | 125,966 | D | ↗ |
| 2023-11-28 | Paley Jeffrey | Director | S-Sale | D | Common Stock, par value $0.0001 per share | 1,745 | 5.22 | 9.1K | 70,727 | — | ↗ |
| 2023-11-08 | Paley Jeffrey | Director | S-Sale | D | Common Stock, par value $0.0001 per share | 255 | 3.76 | 958.80 | 114,217 | — | ↗ |
| 2023-11-07 | Paley Jeffrey | Director | S-Sale | D | Common Stock, par value $0.0001 per share | 2,245 | 3.48 | 7.8K | 114,472 | — | ↗ |
| 2023-10-13 | Smith Justin Adam | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 33,000 | 2.98 | 98.3K | 104,717 | — | ↗ |
| 2023-10-06 | Paley Jeffrey | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 15,000 | 2.98 | 44.7K | 72,472 | — | ↗ |
| 2023-09-21 | Paley Jeffrey | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 30,000 | 2.97 | 89.1K | 57,472 | — | ↗ |
| 2023-09-06 | ROSENWALD LINDSAY A MD | Director | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 2.23 | 223.0K | 114,245 | — | ↗ |
| 2023-09-06 | Maraoui Claude | Director / Officer | P-Purchase | A | Common Stock, par value $0.0001 per share | 26,044 | 2.52 | 65.6K | 2,153,430 | — | ↗ |
| 2023-07-24 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 20,767 | 1.76 | 36.5K | 2,127,386 | — | ↗ |
| 2023-07-24 | Benesch Joseph | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 4,072 | 1.76 | 7.2K | 63,160 | — | ↗ |
| 2023-07-21 | Toledano Miranda Jayne | Director | A-Award | A | Common Stock, par value $0.0001 per share | 27,472 | 0.00 | — | 71,717 | — | ↗ |
| 2023-07-21 | Smith Justin Adam | Director | A-Award | A | Common Stock, par value $0.0001 per share | 27,472 | 0.00 | — | 71,717 | — | ↗ |
| 2023-07-21 | Paley Jeffrey | Director | A-Award | A | Common Stock, par value $0.0001 per share | 27,472 | 0.00 | — | 71,717 | — | ↗ |
| 2023-07-21 | Herskowitz Neil | Director | A-Award | A | Common Stock, par value $0.0001 per share | 27,472 | 0.00 | — | 71,717 | — | ↗ |
| 2023-05-17 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 24,377 | 1.34 | 32.7K | 2,148,153 | — | ↗ |
| 2023-05-16 | Maraoui Claude | Director / Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 20,000 | 1.25 | 25.0K | 2,172,530 | — | ↗ |
| 2023-05-12 | Fortress Biotech, Inc. | 10% Owner | J-Other | D | COMMON STOCK, PAR VALUE $0.0001 | 50,000 | 0.00 | — | 3,860,467 | — | ↗ |
| 2023-02-22 | Benesch Joseph | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 2,768 | 1.97 | 5.5K | 67,232 | — | ↗ |
| 2023-02-12 | Fortress Biotech, Inc. | 10% Owner | J-Other | D | COMMON STOCK, PAR VALUE $0.0001 | 50,000 | 0.00 | — | 3,910,467 | — | ↗ |
| 2023-01-27 | Benesch Joseph | Officer | — | D | Common Stock | 0 | 0.00 | — | 70,000 | — | ↗ |
| 2022-11-12 | Fortress Biotech, Inc. | 10% Owner | J-Other | D | COMMON STOCK, PAR VALUE $0.0001 | 50,000 | 0.00 | — | 3,960,467 | — | ↗ |
| 2022-10-04 | De Paolantonio Ernest Robert | Officer | S-Sale | D | Common Stock, par value $0.0001 per share | 10,093 | 2.41 | 24.3K | 259,907 | — | ↗ |
| 2022-08-12 | Fortress Biotech, Inc. | 10% Owner | J-Other | D | COMMON STOCK, PAR VALUE $0.0001 | 50,000 | 0.00 | — | 4,010,467 | — | ↗ |
| 2022-07-21 | Toledano Miranda Jayne | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,245 | 0.00 | — | 44,245 | — | ↗ |
| 2022-07-21 | Smith Justin Adam | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,245 | 0.00 | — | 44,245 | — | ↗ |
| 2022-07-21 | ROSENWALD LINDSAY A MD | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,245 | 0.00 | — | 14,245 | — | ↗ |
| 2022-07-21 | Paley Jeffrey | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,245 | 0.00 | — | 44,245 | — | ↗ |
| 2022-07-21 | Maraoui Claude | Officer | A-Award | A | Common Stock, par value $0.0001 per share | 300,000 | 0.00 | — | 2,192,530 | — | ↗ |
| 2022-07-21 | Herskowitz Neil | Director | A-Award | A | Common Stock, par value $0.0001 per share | 14,245 | 0.00 | — | 44,245 | — | ↗ |
| 2022-07-21 | De Paolantonio Ernest Robert | Officer | A-Award | A | Common Stock, par value $0.0001 per share | 150,000 | 0.00 | — | 270,000 | — | ↗ |
| 2022-05-12 | Fortress Biotech, Inc. | 10% Owner | J-Other | D | COMMON STOCK, PAR VALUE $0.0001 | 50,000 | 0.00 | — | 4,060,467 | — | ↗ |
| 2022-01-14 | Toledano Miranda Jayne | Director | A-Award | A | COMMON STOCK | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-01-14 | Smith Justin Adam | Director | A-Award | A | COMMON STOCK | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-01-14 | Paley Jeffrey | Director | A-Award | A | COMMON STOCK | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-01-14 | Herskowitz Neil | Director | A-Award | A | COMMON STOCK | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-01-14 | De Paolantonio Ernest Robert | Officer | A-Award | A | COMMON STOCK | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2021-11-26 | ROSENWALD LINDSAY A MD | Director | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 176,470 | — | ↗ |
| 2021-11-16 | Toledano Miranda Jayne | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-16 | Smith Justin Adam | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-16 | Paley Jeffrey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-16 | Maraoui Claude | Director / Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 1,804,024 | — | ↗ |
| 2021-11-16 | Herskowitz Neil | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-16 | Fortress Biotech, Inc. | 10% Owner | — | D | Common stock - Class A, $0.0001 par value | 6,000,000 | 0.00 | — | 0 | — | ↗ |
| 2021-11-16 | De Paolantonio Ernest Robert | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-20 | Sebelius Kathleen | Director | D-Return | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2020-02-20 | RINGO WILLIAM R | Director | D-Return | D | Director Stock Option (right to buy) | 10,344 | 28.82 | 298.1K | 0 | — | ↗ |
| 2020-02-20 | MCDADE MARK | Director | D-Return | D | Director Stock Option (right to buy) | 6,000 | 28.01 | 168.1K | 0 | — | ↗ |
| 2020-02-20 | Lyons-Williams Lori | Officer | D-Return | D | Common Stock | 25,401 | 18.75 | 476.3K | 0 | — | ↗ |
| 2020-02-20 | Gilbert Halley E | Director | D-Return | D | Director Stock Options (Right to buy) | 20,000 | 8.05 | 161.0K | 0 | — | ↗ |
| 2020-02-20 | GUGGENHIME ANDREW | Officer | D-Return | D | Stock Options (Right to buy) | 121 | 5.51 | 664.03 | 0 | — | ↗ |
| 2020-02-20 | Fust Matthew K | Director | D-Return | D | Director Stock Option (right to buy) | 10,344 | 16.00 | 165.5K | 0 | — | ↗ |
| 2020-02-20 | Cohen David E | Director | D-Return | D | Director Stock Stock Option (Right to buy) | 8,620 | 0.99 | 8.5K | 0 | — | ↗ |
| 2020-02-20 | CRAVES FRED B | Director | D-Return | D | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 0 | — | ↗ |
| 2020-02-20 | Bald Eagle Acquisition Corp | 10% Owner | P-Purchase | A | Common Stock | 40,926,025 | 18.75 | 767.36M | 100 | — | ↗ |
| 2020-02-20 | BAUER EUGENE A | Director / Officer | D-Return | D | Common Stock | 16,206 | 18.75 | 303.9K | 0 | — | ↗ |
| 2020-02-11 | BAUER EUGENE A | Director / Officer | G-Gift | D | Common Stock | 10,772 | 0.00 | — | 16,206 | — | ↗ |
| 2020-01-10 | Bald Eagle Acquisition Corp | 10% Owner | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-24 | Fust Matthew K | Director | S-Sale | D | Common Stock | 3,000 | 15.00 | 45.0K | 5,051 | — | ↗ |
| 2019-12-12 | Fust Matthew K | Director | S-Sale | D | Common Stock | 3,000 | 12.00 | 36.0K | 8,051 | — | ↗ |
| 2019-11-11 | Gilbert Halley E | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-12 | Fust Matthew K | Director | S-Sale | D | Common Stock | 6,000 | 8.77 | 52.6K | 11,051 | — | ↗ |
| 2019-08-15 | Lyons-Williams Lori | Officer | F-InKind | D | Common Stock | 1,582 | 7.91 | 12.5K | 25,401 | — | ↗ |
| 2019-08-15 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Restricted Stock Unit | 3,563 | 0.00 | — | 3,562 | — | ↗ |
| 2019-08-15 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Restricted Stock Unit | 2,438 | 0.00 | — | 2,437 | — | ↗ |
| 2019-06-12 | Sebelius Kathleen | Director | M-Exempt | D | Common Stock | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2019-06-12 | RINGO WILLIAM R | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 6,000 | — | ↗ |
| 2019-06-12 | MCDADE MARK | Director | M-Exempt | D | Common Stock | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2019-06-12 | Fust Matthew K | Director | M-Exempt | D | Common Stock | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2019-06-12 | Cohen David E | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 35,682 | — | ↗ |
| 2019-06-12 | CRAVES FRED B | Director / 10% Owner | M-Exempt | D | Common Stock | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2019-06-04 | Sebelius Kathleen | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2019-06-04 | RINGO WILLIAM R | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.38 | 56.3K | 6,000 | — | ↗ |
| 2019-06-04 | MCDADE MARK | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.38 | 56.3K | 6,000 | — | ↗ |
| 2019-06-04 | Fust Matthew K | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2019-06-04 | Cohen David E | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2019-06-04 | CRAVES FRED B | Director / 10% Owner | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2019-05-17 | Lyons-Williams Lori | Officer | F-InKind | D | Common Stock | 10,374 | 10.50 | 108.9K | 23,794 | — | ↗ |
| 2019-05-17 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2019-04-08 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 35,000 | 1.22 | 42.6K | 103,258 | — | ↗ |
| 2019-02-12 | Lyons-Williams Lori | Officer | A-Award | A | Employee Stock Options (Right to buy) | 65,000 | 7.42 | 482.3K | 65,000 | — | ↗ |
| 2019-02-12 | GUGGENHIME ANDREW | Officer | A-Award | A | Employee Stock Options (Right to buy) | 65,000 | 7.42 | 482.3K | 65,000 | — | ↗ |
| 2019-02-12 | BAUER EUGENE A | Director / Officer | A-Award | A | Restricted Stock Unit | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2018-10-19 | Fust Matthew K | Director | S-Sale | D | Common Stock | 4,000 | 13.75 | 55.0K | 14,051 | — | ↗ |
| 2018-08-15 | Lyons-Williams Lori | Officer | F-InKind | D | Common Stock | 368 | 9.58 | 3.5K | 2,616 | — | ↗ |
| 2018-08-15 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Restricted Stock Unit | 3,563 | 0.00 | — | 3,562 | — | ↗ |
| 2018-08-15 | BAUER EUGENE A | Director / Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2018-06-13 | Sebelius Kathleen | Director | M-Exempt | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2018-06-13 | RINGO WILLIAM R | Director | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2018-06-13 | MCDADE MARK | Director | M-Exempt | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2018-06-13 | Fust Matthew K | Director | M-Exempt | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2018-06-13 | Cohen David E | Director | M-Exempt | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2018-06-13 | CRAVES FRED B | Director / 10% Owner | M-Exempt | D | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | — | ↗ |
| 2018-06-12 | Sebelius Kathleen | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 6,000 | — | ↗ |
| 2018-06-12 | RINGO WILLIAM R | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 6,000 | — | ↗ |
| 2018-06-12 | MCDADE MARK | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 6,000 | — | ↗ |
| 2018-06-12 | Fust Matthew K | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 6,000 | — | ↗ |
| 2018-06-12 | Cohen David E | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 9.95 | 59.7K | 6,000 | — | ↗ |
| 2018-06-12 | CRAVES FRED B | Director / 10% Owner | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2018-03-02 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 2,500 | 1.22 | 3.0K | 8,972 | — | ↗ |
| 2018-03-01 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 25.85 | 15.5K | 29,682 | — | ↗ |
| 2018-03-01 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 500 | 1.22 | 609.00 | 11,472 | — | ↗ |
| 2018-02-15 | Lyons-Williams Lori | Officer | A-Award | A | Employee Stock Options (Right to buy) | 63,750 | 28.25 | 1.80M | 63,750 | — | ↗ |
| 2018-02-15 | GUGGENHIME ANDREW | Officer | A-Award | A | Restricted Stock Unit | 9,500 | 0.00 | — | 9,500 | — | ↗ |
| 2018-02-15 | BAUER EUGENE A | Director / Officer | A-Award | A | Employee Stock Options (Right to buy) | 57,000 | 28.25 | 1.61M | 57,000 | — | ↗ |
| 2018-02-01 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 28.87 | 17.3K | 30,282 | — | ↗ |
| 2018-02-01 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 3,000 | 1.22 | 3.7K | 11,972 | — | ↗ |
| 2018-01-02 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 28.03 | 16.8K | 30,882 | — | ↗ |
| 2018-01-02 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 100 | 28.03 | 2.8K | 2,802 | — | ↗ |
| 2017-12-18 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 3,000 | 27.34 | 82.0K | 3,826 | — | ↗ |
| 2017-12-15 | ROSENWALD LINDSAY A MD | Director | — | D | Common Stock Warrant | 500,000 | 0.60 | 298.0K | 0 | — | ↗ |
| 2017-12-01 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 25.49 | 15.3K | 31,482 | — | ↗ |
| 2017-11-01 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 26.82 | 16.1K | 32,082 | — | ↗ |
| 2017-10-11 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 7,500 | 30.04 | 225.3K | 26,978 | — | ↗ |
| 2017-10-02 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 26.99 | 16.2K | 32,682 | — | ↗ |
| 2017-09-01 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 23.56 | 14.1K | 33,282 | — | ↗ |
| 2017-08-28 | Cohen David E | Director | S-Sale | D | Common Stock | 600 | 23.81 | 14.3K | 33,882 | — | ↗ |
| 2017-08-15 | GUGGENHIME ANDREW | Officer | M-Exempt | A | Common Stock | 3,562 | 0.00 | — | 10,671 | — | ↗ |
| 2017-08-15 | BAUER EUGENE A | Director / Officer | M-Exempt | A | Common Stock | 2,625 | 0.00 | — | 7,653 | — | ↗ |
| 2017-08-14 | CRAVES FRED B | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 23.95 | 239.5K | 30,000 | — | ↗ |
| 2017-08-10 | CRAVES FRED B | Director / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 22.57 | 451.5K | 20,000 | — | ↗ |
| 2017-07-05 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 30.00 | 75.0K | 34,478 | — | ↗ |
| 2017-06-20 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 30.01 | 75.0K | 36,978 | — | ↗ |
| 2017-06-13 | Sebelius Kathleen | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2017-06-13 | RINGO WILLIAM R | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2017-06-13 | MCDADE MARK | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 28.01 | 168.1K | 6,000 | — | ↗ |
| 2017-06-13 | Fust Matthew K | Director | A-Award | A | Director Stock Option (right to buy) | 6,000 | 28.01 | 168.1K | 6,000 | — | ↗ |
| 2017-06-13 | Cohen David E | Director | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2017-06-13 | CRAVES FRED B | Director / 10% Owner | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | — | ↗ |
| 2017-05-01 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 18,275 | — | ↗ |
| 2017-05-01 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 33.65 | 84.1K | 39,478 | — | ↗ |
| 2017-04-03 | RINGO WILLIAM R | Director | S-Sale | D | Common Stock | 500 | 34.03 | 17.0K | 0 | — | ↗ |
| 2017-04-03 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 521 | 34.03 | 17.7K | 41,978 | — | ↗ |
| 2017-03-01 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 19,275 | — | ↗ |
| 2017-03-01 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 100 | 35.89 | 3.6K | 44,478 | — | ↗ |
| 2017-02-17 | GUGGENHIME ANDREW | Officer | A-Award | A | Employee Stock Options (Right to buy) | 71,250 | 33.84 | 2.41M | 71,250 | — | ↗ |
| 2017-02-17 | BAUER EUGENE A | Director / Officer | A-Award | A | Employee Stock Options (Right to buy) | 48,750 | 33.84 | 1.65M | 48,750 | — | ↗ |
| 2017-02-15 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 19,775 | — | ↗ |
| 2017-02-14 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 1,505 | 30.00 | 45.2K | 46,978 | — | ↗ |
| 2017-02-01 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 995 | 30.00 | 29.9K | 48,483 | — | ↗ |
| 2017-01-09 | Lyons-Williams Lori | Officer | A-Award | A | Employee Stock Options (Right to buy) | 100,000 | 31.87 | 3.19M | 100,000 | — | ↗ |
| 2017-01-04 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 20,275 | — | ↗ |
| 2017-01-03 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 30.07 | 75.2K | 49,478 | — | ↗ |
| 2016-12-16 | RINGO WILLIAM R | Director | M-Exempt | A | Common Stock | 125 | 16.00 | 2.0K | 125 | — | ↗ |
| 2016-12-14 | BAUER EUGENE A | Director / Officer | S-Sale | D | Common Stock | 2,300 | 30.27 | 69.6K | 52,178 | — | ↗ |
| 2016-12-12 | Lyons-Williams Lori | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-01 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 375 | 16.00 | 6.0K | 20,900 | — | ↗ |
| 2016-11-09 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 21,275 | — | ↗ |
| 2016-11-09 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 4,100 | 5.51 | 22.6K | 120,513 | — | ↗ |
| 2016-10-11 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 10,900 | 5.51 | 60.1K | 124,613 | — | ↗ |
| 2016-10-03 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 21,775 | — | ↗ |
| 2016-09-19 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Employee Stock Options (Right to buy) | 15,000 | 5.51 | 82.7K | 135,513 | — | ↗ |
| 2016-09-12 | GUGGENHIME ANDREW | Officer | M-Exempt | A | Common Stock | 10,000 | 5.51 | 55.1K | 15,116 | — | ↗ |
| 2016-09-01 | RINGO WILLIAM R | Director | M-Exempt | D | Director Stock Option (right to buy) | 500 | 16.00 | 8.0K | 22,275 | — | ↗ |
| 2016-08-15 | GUGGENHIME ANDREW | Officer | M-Exempt | D | Restricted Stock Unit | 1,188 | 0.00 | — | 10,687 | — | ↗ |
| 2016-08-15 | BAUER EUGENE A | Director / Officer | M-Exempt | D | Restricted Stock Unit | 875 | 0.00 | — | 7,875 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-140.9K
Shares Outstanding
27.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Claude Maraoui President and Chief Executive Officer | 583.5K | — | 310.9K | 404.7K | 352.7K | 14.0K | 1.67M | 42.96% | ↗ |
| 2 | 2025 | Ramsey Alloush Chief Operating Officer, Corporate Secretary and General Counsel | 392.9K | — | 295.7K | 306.5K | 185.0K | 14.0K | 1.19M | 50.43% | ↗ |
| 3 | 2025 | Joseph Benesch Chief Financial Officer | 318.3K | — | 182.4K | 204.3K | 114.3K | 4.4K | 823.7K | 46.95% | ↗ |
| 4 | 2024 | Claude Maraoui President and Chief Executive Officer | 566.5K | — | 1.62M | — | 395.1K | 13.8K | 2.60M | 62.45% | ↗ |
| 5 | 2024 | Claude Maraoui Chief Executive Officer | 566.5K | — | 1.62M | — | 395.1K | 13.8K | 2.60M | 62.45% | ↗ |
| 6 | 2024 | Ramsey Alloush Chief Operating Officer, Corporate Secretary and General Counsel | 360.5K | — | 1.02M | — | 180.3K | 13.8K | 1.57M | 64.75% | ↗ |
| 7 | 2024 | Joseph Benesch Chief Financial Officer | 309.0K | — | 741.6K | — | 117.4K | 7.7K | 1.18M | 63.08% | ↗ |
| 8 | 2023 | Claude Maraoui Chief Executive Officer | 550.0K | — | — | — | 371.3K | 13.2K | 934.5K | 0.00% | ↗ |
| 9 | 2023 | Joseph Benesch Chief Financial Officer | 300.0K | — | — | — | 103.2K | 5.8K | 409.0K | 0.00% | ↗ |
| 10 | 2023 | Ernie De Paolantonio Former Chief Financial Officer | 31.7K | — | — | — | — | 1.3K | 33.0K | 0.00% | ↗ |
| 11 | 2022 | Claude Maraoui Chief Executive Officer | 473.9K | — | 1.05M | — | 334.2K | 12.2K | 1.87M | 56.21% | ↗ |
| 12 | 2022 | Ernie De Paolantonio Chief Financial Officer | 306.8K | — | 1.14M | — | — | 12.2K | 1.46M | 78.13% | ↗ |
| 13 | 2022 | Ernie De Paolantonio Former Chief Financial Officer | 306.8K | — | 1.14M | — | — | 12.2K | 1.46M | 78.13% | ↗ |
| 14 | 2021 | Claude Maraoui Chief Executive Officer | 463.5K | — | 631.0K | — | 463.5K | 11.6K | 1.57M | 40.20% | ↗ |
| 15 | 2021 | Nirav Jhaveri Former Chief Executive Officer | 250.5K | 275.0K | — | — | — | 2.3K | 527.8K | 0.00% | ↗ |
| 16 | 2021 | Ernie De Paolantonio Chief Financial Officer | 76.4K | 50.0K | — | — | 22.5K | 1.5K | 150.4K | 0.00% | ↗ |
| 17 | 2020 | Claude Maraoui Chief Executive Officer | 450.0K | — | 1.19M | — | 450.0K | 11.4K | 2.10M | 56.69% | ↗ |
| 18 | 2020 | Nirav Jhaveri Former Chief Executive Officer | 281.2K | — | 219.1K | — | — | 1.2K | 501.4K | 43.69% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Claude Maraoui | Founder, President, Chief Executive Officer & Director | 950.2K | male |
| Ramsey Alloush | Chief Operating Officer, General Counsel & Company Secretary | 592.0K | male |
| Joseph Benesch | Chief Financial Officer & Corporate Controller | 437.0K | male |
| Lindsay Allan Rosenwald | Executive Chairman | 50.0K | — |
| Louis Donati | Director of Market Access | — | male |
| Jaclyn Jaffe | Senior Director of Corporate Operations | — | — |
| Robert Nevin | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DERM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
